Erik Bloomquist

3.9k total citations · 1 hit paper
35 papers, 1.8k citations indexed

About

Erik Bloomquist is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Erik Bloomquist has authored 35 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Erik Bloomquist's work include Advanced Breast Cancer Therapies (10 papers), Breast Cancer Treatment Studies (8 papers) and Renal cell carcinoma treatment (7 papers). Erik Bloomquist is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), Breast Cancer Treatment Studies (8 papers) and Renal cell carcinoma treatment (7 papers). Erik Bloomquist collaborates with scholars based in United States and Belgium. Erik Bloomquist's co-authors include Marc A. Suchard, Vladimir N. Minin, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani, Rajeshwari Sridhara, Shenghui Tang, Suparna Wedam, Kirsten B. Goldberg and Marc R. Theoret and has published in prestigious journals such as Journal of Clinical Oncology, Trends in Ecology & Evolution and Cancer Research.

In The Last Decade

Erik Bloomquist

32 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Smooth Skyride through a Rough Skyline: Bayesian Coalescent-Based Inference of Population Dynamics

2008 529 citations Vladimir N. Minin, Erik Bloomquist et al. Molecular Biology and Evolution profile →

Peers

Countries citing papers authored by Erik Bloomquist

Since Specialization

Citations

This map shows the geographic impact of Erik Bloomquist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Bloomquist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Bloomquist more than expected).

Fields of papers citing papers by Erik Bloomquist

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Bloomquist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Bloomquist. The network helps show where Erik Bloomquist may publish in the future.

Co-authorship network of co-authors of Erik Bloomquist

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Bloomquist. A scholar is included among the top collaborators of Erik Bloomquist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Bloomquist. Erik Bloomquist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials 2025 ·JNCI Cancer Spectrum ·Elaine Chang, Haley Gittleman, (unknown), Erik Bloomquist, (unknown), Chana Weinstock, Sundeep Agrawal, Nicole Gormley, Shenghui Tang, Daniel L. Suzman, Laleh Amiri‐Kordestani, Richard Pazdur, Paul G. Kluetz, David H. McDermott, Meredith M. Regan, Brian I. Rini	0
2	FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma 2024 ·Clinical Cancer Research ·William F. Maguire, Daniel Lee, Chana Weinstock, Xin Gao, Catharine C. Bulik, Sundeep Agrawal, Elaine Chang, Salaheldin S. Hamed, Erik Bloomquist, Shenghui Tang, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani, Daniel L. Suzman	13
3	FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials. 2023 ·Journal of Clinical Oncology ·Elaine Chang, Haley Gittleman, (unknown), Erik Bloomquist, Chana Weinstock, Sundeep Agrawal, Rajeshwari Sridhara, Nicole Gormley, Laleh Amiri‐Kordestani, Shenghui Tang, Paul G. Kluetz, Daniel L. Suzman, Richard Pazdur, David F. McDermott, Meredith M. Regan, Brian I. Rini	0
4	FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer 2023 ·Clinical Cancer Research ·Jennifer Gao, Christy Osgood, (unknown), Erik Bloomquist, Shenghui Tang, (unknown), Tiffany K. Ricks, (unknown), William F. Pierce, Donna R. Rivera, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani	3
5	Regulatory implications of ctDNA in immuno-oncology for solid tumors 2023 ·Journal for ImmunoTherapy of Cancer ·Paz J. Vellanki, Soma Ghosh, Anand Pathak, Michael Fusco, Erik Bloomquist, Shenghui Tang, Harpreet Singh, Reena Philip, Richard Pazdur, Julia A. Beaver	36
6	A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma 2023 ·European Urology ·Daniel Lee, Haley Gittleman, Chana Weinstock, Daniel L. Suzman, Erik Bloomquist, Sundeep Agrawal, Michael H. Brave, (unknown), Jaleh Fallah, Harpreet Singh, Shenghui Tang, Amna Ibrahim, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani	8
7	US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer 2023 ·Journal of Clinical Oncology ·Preeti Narayan, Asma Dilawari, Christy Osgood, (unknown), Erik Bloomquist, William F. Pierce, (unknown), Shyam Kalavar, Marina Kondratovich, (unknown), Soma Ghosh, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani	34
8	Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis 2021 ·The Lancet Oncology ·Jennifer Gao, Joyce Cheng, Tatiana M. Prowell, Erik Bloomquist, Shenghui Tang, Suparna Wedam, Melanie Royce, (unknown), Christy Osgood, Gwynn Ison, Rajeshwari Sridhara, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani	21
9	FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer 2020 ·Clinical Cancer Research ·Suparna Wedam, Lola A. Fashoyin‐Aje, Xin Gao, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Kirsten B. Goldberg, Bellinda L. King‐Kallimanis, Marc R. Theoret, Amna Ibrahim, Laleh Amiri‐Kordestani, Richard Pazdur, Julia A. Beaver	65
10	A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials 2020 ·Annals of Oncology ·Laleh Amiri‐Kordestani, Diqiong Xie, Sara M. Tolaney, Erik Bloomquist, Shenghui Tang, Amna Ibrahim, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, R. Sridhara, Eric P. Winer, Julia A. Beaver	15
11	CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis 2019 ·The Lancet Oncology ·Jennifer Gao, Joyce Cheng, Erik Bloomquist, (unknown), Suparna Wedam, Harpreet Singh, Laleh Amiri‐Kordestani, Amna Ibrahim, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Gideon M. Blumenthal, Richard Pazdur, Julia A. Beaver, Tatiana M. Prowell	194
12	FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer 2019 ·Clinical Cancer Research ·Suparna Wedam, Lola A. Fashoyin‐Aje, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Laleh Amiri‐Kordestani, Richard Pazdur, Julia A. Beaver	102
13	An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast Cancer 2019 ·Therapeutic Innovation & Regulatory Science ·Erik Bloomquist, Susan Jin, (unknown), Shenghui Tang, Rajeshwari Sridhara	0
14	FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer 2018 ·Clinical Cancer Research ·Anand Shah, Erik Bloomquist, Shenghui Tang, Wentao Fu, Youwei Bi, Qi Liu, Jingyu Yu, Ping Zhao, Todd R. Palmby, Kirsten B. Goldberg, (unknown), Paresma Patel, (unknown), Amy Tilley, William F. Pierce, Amna Ibrahim, Gideon M. Blumenthal, Rajeshwari Sridhara, Julia A. Beaver, Richard Pazdur	88
15	U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy 2015 ·The Oncologist ·Erin Larkins, Barbara Scepura, Gideon M. Blumenthal, Erik Bloomquist, Shenghui Tang, (unknown), Paul G. Kluetz, Patricia Keegan, Richard Pazdur	31
16	Three roads diverged? Routes to phylogeographic inference 2010 ·Trends in Ecology & Evolution ·Erik Bloomquist, Philippe Lemey, Marc A. Suchard	80
17	StepBrothers: inferring partially shared ancestries among recombinant viral sequences 2008 ·Biostatistics ·Erik Bloomquist, Karin S. Dorman, Marc A. Suchard	4
18	Smooth Skyride through a Rough Skyline: Bayesian Coalescent-Based Inference of Population Dynamics breakdown → 2008 ·Molecular Biology and Evolution ·Vladimir N. Minin, Erik Bloomquist, Marc A. Suchard	529
19	Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment 2008 ·Computational Statistics & Data Analysis ·Christina M. Ramirez, (unknown), Daniel R. Kuritzkes, Erik Bloomquist, Steven G. Deeks, Marc A. Suchard	5
20	Noninvasive Diagnosis of Cellular and Antibody-Mediated Rejection by Perforin and Granzyme B in Renal Allografts 2006 ·Human Immunology ·Jeffrey L. Veale, (unknown), Qiuheng Zhang, David W. Gjertson, Zeying Du, Erik Bloomquist, Juan Jia, Lei Qian, Alan Wilkinson, Gabriel M. Danovitch, Phuong‐Thu T. Pham, J. Thomas Rosenthal, Charles Lassman, Jonathan Braun, Elaine F. Reed, H. Albin Gritsch	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact